QLS4131 Combination Treatment for Multiple Myeloma and Related Blood Cancers
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a new drug combination called QLS4131 paired with other medications to treat multiple myeloma, plasma cell leukemia, and light-chain amyloidosis—blood cancers caused by abnormal plasma cells. The goal is to see if this combination can help control these diseases better than current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with multiple myeloma, plasma cell leukemia, or light-chain amyloidosis confirmed by your doctor
- You have measurable disease (detectable cancer markers in your blood or urine)
- You have not previously received treatment targeting BCMA, GPRC5D, or CD3 (specific cancer cell markers)
- You have waited at least 4 weeks since your last cancer treatment (or 2 weeks for certain chemotherapy types)
- You have not had a severe allergic or immune reaction (Grade 3 or higher) to similar cell-redirecting therapies before
- You have not had severe side effects from lenalidomide, pomalidomide, or similar drugs in the past
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination therapy for people with multiple myeloma that has returned or not responded to at least one prior treatment. The goal is to see if the combination (QLS32015 plus other drugs) can effectively control the cancer.
This trial tests a new drug, QLS32015, against two common treatments for multiple myeloma that has come back or not responded to therapy. It may be an option for people who have already tried several treatments.
This trial tests a new drug called QLS4131 for people with multiple myeloma that has returned or not responded to treatment. It's a first-in-human study to see if the drug is safe and how well it works.
This trial tests a new drug for people with multiple myeloma, a type of blood cancer. It's for those who are newly diagnosed or whose cancer has come back or stopped responding to treatment. The goal is to see if the drug can control the disease.
This study tests a new drug that targets two proteins on the cells causing amyloidosis, aiming to reduce the harmful protein buildup in the body. It is for people who have just been diagnosed with this condition and have not yet had other treatments for it.
This trial tests a new combination of drugs (CM336, isatuximab, bortezomib, and lenalidomide) for people newly diagnosed with primary plasma cell leukemia, a rare and aggressive blood cancer. It aims to see if this combination can help control the disease better.
Hear when a new Malignant Plasma Cell Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.